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Alb  Albumin 
ATS  American Thoracis Society 
C  grade Celsius  
COPD  Chronic Obstructive Pulmonary Disease 
Cp  heat capacity for constant pressure 
ΔH  calorimetric enthalpy  
ΔH /Jg¯¹ calorimetric enthalpy normalized for mass 
DSC  Differential Scanning Calorimetry  
ERS  European Respiratory Society 
FEV1  forced expiratory volume in one second 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
mMRC modified Medical Research Council Dyspnea Scale 
PFT  pulmonary lung function test 
SD  standard deviation 
Tm  maximal temperature of denaturation 
T/C    maximal denaturation temperature in Celsius 






1. Introduction: topic at a municipal hospital, and the clinical research at 
Pécs 
Throughout my carrier I had a chance to observe how Chronic Obstructive 
Pulmonary Disease (COPD) has become the 'celebrity of pulmonology', turning from 
the diagnostical and even more the therapeutical nihilism into one of the main clinical 
research areas. 
COPD by definition is a preventable and treatable disease, characterized by 
persistent airflow limitation that is usually progressive. It is associated with an 
enhanced chronic inflammatory response in the airways and the lung to noxious 
particles and gases (most common smoking). COPD affects 6% of the adult 
population and is a major global health burden, with a perspective of becoming the 
third cause of death by 2030. COPD is underdiagnosed worldwide. In Hungary the 
registered prevalence was below 1% in 2004 and was 1,8% in 2014, far below the 
estimated 500.000 patient number. The mild COPD has its importance due to the 
accelerated disease progression, and for being an ideal target for early intervention. 
Biomarker research has been the one of the main topics in COPD research, but we 
are still far from finding the perfect indicator that could characterize every aspect of 
the disease. Routine clinical research have changed from the previous GOLD I–IV 
(based on spirometry data) to the present GOLD A–D staging system (based on 
combined risk assessment), but objectivity of staging is less than desired. There is no 
tight correlation between the pathophysiological background and the clinical 
phenotype. Lack of sufficiently specific and properly sensitive biomarkers are 
responsible for a deeper understanding of inflammatory theory and for poor 
identification of individual phenotypes. 
Going back to the topics of the research, in 2004, as a result of structural 
reformation of health care institutions, the 90-bed Department of Pulmonology at 
Újrónafő moved into the Karolina Hospital center at Mosonmagyaróvár. As a result 
of this obligate marriage between pulmonary medicine and the departments of 





these related professions. After a consensual-decision making, we started COPD 
screening among internal (mainly cardiology) inpatients between 2005 and 2011. We 
published our observations achieved by COPD screening in national forums. 
Achievements of this project, comparison of results with other national and 
international screenings, and my suggestions concerning COPD screening are 
summarized in this thesis. 
Since the adoption of the new GOLD (Global Initiative for Chronic Obstructive 
Pulmonary Disease) staging system in 2011, my attentions turned to the COPD 
severity stages, and as biomarker resarch reached a peak in that time, I became more 
interested in the research for new indicators of severity stages and risk factors. The 
theoretical background was already laid down by former researches of Professor 
Tamás F. Molnár [Szanto Z, Kovacs Gy, Nagy V, Roth E, Molnar TF, Horvath OP: 
Differential scanning calorimetric examination of the tracheal cartilage after primary 
reconstruction with differential suturing techniques. Thermochimica Acta 2006; 
445(2):190-194].  With the leadership of Professor Dénes Lőrinczy, an 
internationally acknowledged expert of methodics at the Department of Biophysics, 
Medical School of University of Pécs, we started to extend thermoanalytical 
measurements performed by differential scanning calorimetry (DSC) to COPD. 
Therefore I had a chance to firstly apply this method for the analysis of this barely 
examined disease, and explore the thermodynamic parameters representing the 
different severity stages of COPD. The blood samples for DSC measurements were 
collected from the patients with COPD at Karolina Hospital. Since 2013, I have been 
working at Petz Aladár County Teaching Hospital, so I have continued my research 
along with the bibliographic work there. I have working as a pulmonologist for 30 
years and as Head of Department for 18 years, but still I think that the top of my 
career is marked by my research that could build a bridge between the work at the 












1. Thermonalysis of blood serum of patients at different stages of COPD 
with Differencial Scanning Calorimetry (DSC) method and evaluation the 
feasibility of the method. 
 
2. Evaluation of applicability of the DSC method for distinguishing COPD 
stages. 
 
3. Analysis of the serum denaturation parameters representing different 
stages of the disease depending on smoking status of the patients. 
 
4. Organising a case-finding COPD screening programme in cardiology 
inpatients and evaluation of efficacy.  
 
5. Comparing effectiveness of national COPD screening tests. 
 







3. Patients and methods 
 
      3.1. DSC of blood serum in staging COPD 
Thermal analysis is a method by which physical or chemical properties of a 
sample are measured during heating (or cooling) process. In the study SETARAM 
Micro DSC-II calorimeter was used. The calorimetric enthalpy (ΔH) and the maximal 
temperature of denaturation (Tm ) of the sera were monitored. 20 GOLD I-IV COPD 
patients and 5 smoking and 5 never smoked helthy controls were enrolled in the pilot 
study. Based on those results, 74 GOLD A-D COPD patients’ samples, smokers and 
ex-smokers, in the main study were analysed.  
3.2. COPD screening 
Case finding (opportunistic) screening program using spirometry after general 
medical examination was performed among Cardiology inpatients in Karolina 
Hospital Mosonmagyaróvár between 2005 and 2011. Our results were compared with 
the results of an organised COPD screening program, linked to the national lung 
screening program in Moson county, between 2009-2012.    
 
4.  Results 
4.1. Results: DSC in staging COPD  
The pilot study demonstrates the significant difference in the calorimetric 
enthalpy and the maximal denaturation temperatures, when comparing early and 
severe COPD (stage and IV) from eachother and controls in smokers and ex-smokers 







DSC scans of blood serum of smoking COPD I-IV COPD patients  







DSC scans of blood serum of ex-smoker COPD I-IV COPD patients  
and healthy never smoking controls (pilot study) 
 
In healthy controls no significant differences depending on smoking status were 
found either.  As Figure 3. shows there are difference between the maximum of the 
heat flow of the two subgroups, but healthy controls do not differ significantly from 








DSC scans of blood serum of healthy smokers and never smoked control subjects 
 
In the main study 63 samples of 74 were studied, as sera of 11 patients due to power 




       Table 1. 








Taking together the smoker and ex-smoker soubgroups, Table 2. shows the combined 
COPD assesment and patient’s GOLD A-D clinical features.   
 
Table 2. 
Combined COPD assesment and patients features 
¹ Dyspnea based on mMRC  2 points. ² FEV1 values: GOLD I  80%, GOLD:50-80%, GOLD III: 
30-50%, GOLD IV  30%  *serum Alb normal values: 32,4-52,8 g/l 
 
 
Table 3. shows the DSC thermal parameters according to the strata, i.e. smoker and 




Thermal parameters (Tm/C and ΔH/Jg
-1
) in different  





According to the different COPD stages, as Figure 3. shows, from A to D, there are 
clear trends with the increasing severity of the disease expressed either in ΔH /Jg¯¹  
és Tm/C. Enthalpy significantly differs between A and D. Focusing on Tm there is a 




The change in thermal parameters (Tm/C and ΔH/Jg
-1
) in the different severity of COPD in case of smokers 




The DSC scans are specific for different pathologies. They serve as a fingerprint for 
the progression of lung disease in COPD patients. Significant differences of 
denaturation parameters, eg. between B-D and A-C groups can be seen as it is 












The heat flow – temperature DSC scans in different 





4.2. Results: COPD screening 
414 Cardiology inpatients were screened using spirometry between 2005 és 
2011 között. The „prescreenings” were performed by the cardiologists, during 
general patient assesment. As result of screening, 37 patient was found asthmatic and 
327 having COPD. The 2/3 of COPD patients were older than 60, 3/4 of them were 
heavy smokers (more than 30-40 pack-year) and 2/3 of them were clasified in GOLD 
II stage. Table 4. summarizes the prevalence and incidence of COPD in Moson 









Prevalence and incidence of COPD in Moson county and the percentage of patients identified 
with opportunistic screening 
 
 
Another screening program was studied, the one organised by the national lung 
screening program staff, between 2009 and 2012, using the WHO COPD symptome 
test as presceening tool, followed by lung function testing.  220 of 599 individuals 
had a negative questionnaire and 72 spirometry measurements were uninterpretable. 
39 of 599 were found to have obstructive lung function, and finally 29 were 
diagnosed of having COPD, as it is exhibited in Table 5. 
                        
Table 5. 







5.1. DSC in staging COPD 
This was the first time worldwide when COPD GOLD A-D stages were 
assessed by analysing the thermal parameters of blood sera using DSC method. Based 
on the results of the pilot and the main experiments, we concluded that thermal 
parameters of the sera acquired from COPD patients, the enthalpy change (ΔH) and 
the maximal temperature of denaturation (Tm), map the severity and risk stages of 
GOLD A-D, and that these are proportional to the level of severity and independent 
of the actual smoking habits of the patient. The peak denaturation temperature can 
differentiate dyspneic (B, D) and asymptomatic (A, C) subgroups, both in smoker and 
ex-smoker groups. We reached similar conclusions that were published by others in 
relation to the analysis of plasma or sera of patients with inflammatory diseases or 
certain types of cancer: DSC curves were well distinguishable and characteristic to 
the disease and to the different stages of the disease. Our results can be explained by 
the results of other published DSC analyses: calorimetric changes are not directly 
related to quantitative changes of the components, but rather to the results of so called 
„interactoma”: certain biomarkers (but not identifiable by this method) of COPD 
stages, interact with the proteins of the „proteoma”. 
 
5.2. COPD screening 
         Our model is the first and up till now the only published opportunistic COPD 
screening model in cardiac inpatients in Hungary. With this method the screening 
efficiency of obstructive respiratory disease was outstanding, 87.9 %. Using the 
selected criteria, the 'hit rate' of COPD patients was also outstandingly high, 78.9%. 
Medical pre-screening by a doctor (in this case a cardiologist) is efficient, even 
though in this particular patient group the symptoms can be masked by the symptoms 





the literature. The other reviewed model, organised screening linked to national lung 
screening, is the counterexample with its many defaults, and shows how screening 
should not be organised and performed. Main defects of this type of screening are the 
inaccurate survey of the patient group (loosely defined interpretation of the 
questionnaires), the overweight of the young (according to the disease) population 
and the bad quality of lung function testing. These together resulted in a very low, 1,3 
% screening efficiency along with the wasting of resources. Population COPD 
screening is not recommended by any of the professional organisations. The situation 
is different with opportunistic (case-finding) screening tests. Many positive examples 
are known worldwide, and it has become clear now that the key to success is to 
appropriately design the screening.  
 
5.2.1. Suggestions for optimization of COPD screening 
Summarizing data from international literature, considering peculiarities of the 
Hungarian pulmonology care, and the experiences from national and our own 
screening program, the following evidence-based recommendations can be stated 
towards the professionals and the policy-makers regarding optimization of national 
COPD screening, i.e. finding patients. 
a. COPD screening is recommended only in opportunistic (case finding) form, 
that can be ad hoc or campaign-like. 
b. Suggestions for selecting the patients: at least 40 years old men and women, 
smokers or ex-smokers, with a history of at least 10 package years of smoking. 
Hit rate can be increased and resource cost decreased if the age limit is raised 
to 50 years and smoking packyears to 20.  
c. The most effective pre-screening is the medical examination, therefore it is 
very important to emphasize the significance of continuous education for 
doctors working in related professions (general practitioners, internists, 





d. The use of pre-screening questionnaires is optional, and only validated 
questionnaires should be used. Questionnaires that are not sensitive enough 
and overvaluation of symptoms increase the number of needless spirometries. 
Moreover, questionnaires not specific enough or only adequate for estimating 
symptoms, may exclude the discovery of patients without symptoms.  
e. The quality of the lung function test is crucial, therefore the rules of the 
profession (ERS/ATS guidelines) must be respected and quality control must 
be performed throughout the whole screening process. 
f. Spirometric screening linked to population lung screening may be effective 
only if the target group is appropriately chosen.  
g. COPD screening in cardiac patients proved to be extremely effective, therefore 
we recommend to introduce this in hospitals where more professions are 
merged. 
h. COPD screening is also a good opportunity to promote smoking cessation. 
 
 
6. New results and conclusions of the theses 
1. This was the first case wirldwide when thermal parameters of blood sera 
of COPD patients at GOLD A-D stages were analysed by differential 
scanning calorimetry method (DSC). DSC was proved to be a reliable 
and feasible method in COPD research. 
 
2. COPD severity stages can be distinguished with DSC. Significant 
differences were found between enthalpy changes (ΔH) and in the 
maximal temperature of denaturation (Tm) of the mild (A) and the 
severe, high risk, often exacerbating (D) groups. Significant differences 
were found in the Tm between less dyspneic (GOLD A, C) and dyspnoeic 






3. Changes in thermal parameters are not significantly affected by actual 
smoking in the samples of healthy people and COPD patients at GOLD 
A-B stages. Smoking-dependent differences were found in Tm within the 
GOLD C and D groups. The reverse enthalpy change in the group of 
smokers at stage GOLD D can be a sign of 'burnout' of the disease. 
 
4. This was the first time when COPD screening was performed in cardiac 
patients in Hungary, and the method proved to be extremely effective, 
sufficiently specific and sensitive, based on the high hit rate. The reason 
of high hit rate was the medical 'pre-screening' preceding spirometry.  
 
5. Population COPD screening is not supported by our results, that is 
consistent with data from literature. It can be stated that COPD 
screening is recommended only in a case finding, opportunistic form. 
 
6. Summarizing data from our research, national experiences and 
international literature, evidence-based recommendations were phrased 
regarding optimization of national COPD screening and discovering 
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